Blood, 15 September 2006, Vol. 108, No. 6, pp. 1979-1983.
Prepublished online as a Blood First Edition Paper on June 1, 2006; DOI 10.1182/blood-2006-04-015784.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Immunoglobulin free light chains and solitary plasmacytoma of bone
David Dingli,
Robert A. Kyle,
S. Vincent Rajkumar,
Grzegorz S. Nowakowski,
Dirk R. Larson,
John P. Bida,
Morie A. Gertz,
Terry M. Therneau,
L. Joseph Melton, III,
Angela Dispenzieri, and
Jerry A. Katzmann
From the Division of Hematology, the Department of Health Sciences Research, and the Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN.
An abnormal serum immunoglobulin free light chain (FLC) ratio at diagnosis may identify risk of progression to myeloma in patients with solitary bone plasmacytoma (SBP). In the cohort of 116 patients, 43 have progressed to myeloma, with a median time to progression of 1.8 years. The FLC ratio was determined in all 116 patients on serum collected at time of diagnosis and was abnormal in 54 patients (47%). An abnormal FLC ratio was associated with a higher risk of progression to myeloma (P = .039). The risk of progression at 5 years was 44% in patients with an abnormal serum FLC ratio at diagnosis compared with 26% in those with a normal FLC ratio. One to 2 years following diagnosis, a persistent serum M protein level of 5 g/L (0.5 g/dL) or higher was an additional risk factor for progression. A risk stratification model was constructed using the 2 variables of FLC ratio and M protein level: patients with a normal FLC ratio at baseline and M protein level less than 5 g/L (0.5 g/dL) at 1 to 2 years following diagnosis (low risk, n = 31); with either risk factor abnormal (intermediate risk, n = 26); and with both an abnormal FLC ratio and M protein level of 5 g/L (0.5 g/dL) or higher (high risk, n = 18). The corresponding progression rates at 5 years were significantly different in the low, intermediate, and high groups: 13%, 26%, and 62%, respectively (P < .001).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Dispenzieri, L. Zhang, J. A. Katzmann, M. Snyder, E. Blood, R. DeGoey, K. Henderson, R. A. Kyle, M. M. Oken, A. R. Bradwell, et al.
Appraisal of immunoglobulin free light chain as a marker of response
Blood,
May 15, 2008;
111(10):
4908 - 4915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, R. A. Kyle, J. A. Katzmann, T. M. Therneau, D. Larson, J. Benson, R. J. Clark, L. J. Melton III, M. A. Gertz, S. K. Kumar, et al.
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Blood,
January 15, 2008;
111(2):
785 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
